Inventors:
A. Grey Craig - Solana Beach CA
David Griffen - Greenville NC
Baldomero M. Olivera - Salt Lake City UT
Maren Watkins - Salt Lake City UT
David R. Hillyard - Salt Lake City UT
Julita Imperial - Salt Lake City UT
Lourdes J. Cruz - Manila, PH
John D. Wagstaff - Satl Lake City UT
Richard T. Layer - Sandy UT
Robert M. Jones - Salt Lake City UT
R. Tyler McCabe - Salt Lake City UT
Assignee:
University of Utah Research Foundation - Salt Lake City UT
Cognetix, Inc. - Salt Lake City UT
International Classification:
A01N 3718
US Classification:
514 2, 514 13, 514 14, 530324, 530325, 530326
Abstract:
The present invention is directed to contulakin-G (which is the native glycosylated peptide), a des-glycosylated contulakin-G (termed Thr -contulakin-G), and derivatives thereof, to a cDNA clone encoding a precursor of this mature peptide and to a precursor peptide. The invention is further directed to the use of this peptide as a therapeutic for anti-seizure, anti-inflammatory, anti-shock, anti-thrombus, hypotensive, analgesia, anti-psychotic, Parkinsons disease, gastrointestinal disorders, depressive states, cognitive dysfunction, anxiety, tardive dyskinesia, drug dependency, panic attack, mania, irritable bowel syndrome, diarrhea, ulcer, GI tumors, Tourettes syndrome, Huntingtons chorea, vascular leakage, anti-arteriosclerosis, vascular and vasodilation disorders, as well as neurological, neuropharmalogical and neuropsychopharmacological disorders.